Back to news and publications

Strata Oncology announces new partnerships with Aurora Health and UT Health

Strata Precision Oncology Network now includes 10 healthcare systems providing no-cost tumor profiling and clinical trials system-wide

March 13, 2018

March 13, 2018

Strata Oncology, a precision oncology company, today announced that Aurora Health Care, the largest healthcare system in Wisconsin, and University of Texas Health Sciences at Houston (UTHealth) have joined the Strata Precision Oncology Network™ (Network). Formed in 2016 by Strata Oncology, the Network is accelerating precision oncology by providing advanced cancer patients routine access to tumor profiling and matching to a portfolio of biomarker-driven pharma-sponsored clinical trials, and has since expanded to 10 healthcare systems representing more than 85,000 new cancer patients annually.

“We are excited to join a collaborative group of leading cancer centers across the country working to ensure broad, timely patient access to precision medicine,” said Robert J. Amato, DO, Acting Director of the Division of Oncology at UTHealth McGovern Medical School and the Chief of the Division of Oncology at Memorial Hermann Cancer Center-TMC.

Members leverage theStrataNGS™ test, an 87-gene assay that sequences both DNA and RNA, as the foundation of comprehensive, integrated solution to deliver precision oncology system-wide. StrataNGS is available to all advanced solid tumor and lymphoma patients at no cost through the Strata Trial, a nationwide observational study providing tumor profiling and trial matching for 100,000 patients with advanced cancer.

“We welcome Aurora Health Care and UTHealth as partners committed to advancing precision oncology,” said Dan Rhodes, Ph.D., CEO of Strata Oncology. “The Network continues to expand with both academic and community healthcare systems collaborating to lead the way in advancing precision medicine for cancer patients.”

“This partnership reinforces our commitment to transform healthcare and deliver superior clinical outcomes,” said Michael Thompson, MD, PhD, hematologist/oncologist for Aurora Cancer Care and Medical Co-Director, Oncology Precision Medicine Program at Aurora Health Care. “By partnering with Strata Oncology, Aurora Health Care will be one of a select group of health systems in the country offering advanced cancer patients increased access to precision medicine. Eligible cancer patients at Aurora Health Care will have access to tumor molecular profiling, with an opportunity to enroll on cancer clinical trials that will be available at Aurora.”

The Network’s additional members include:

  • Christiana Care’s Helen F. Graham Cancer Center & Research Institute (DE)
  • Kaiser Permanente-Northern California
  • Kettering Health Network (OH)
  • Metro Minnesota Community Oncology Research Consortium
  • Ochsner Health System (LA)
  • UAB Comprehensive Cancer Center
  • UNC Lineberger Comprehensive Cancer Center
  • University of Wisconsin Carbone Cancer Center
Media Inquiries

Rachel Ford Hutman  rachel@fordhutmanmedia.com 301.801.5540

About Strata Oncology

Strata Oncology, Inc. is a precision oncology company dedicated to delivering the best possible treatment for each patient with cancer. The company combines molecular profiling, real-world data, and a large-scale clinical trial platform to identify and deliver optimal treatments for patients with cancer. For more information visit strataoncology.com.

In the news

The latest from Strata Oncology

December 1, 2023

Strata Oncology Announces Presentations on Proprietary Multivariate Biomarkers at North America Conference on Lung Cancer and San Antonio Breast Cancer Symposium

November 8, 2023

Strata Oncology Recognized as “Diagnostics Innovation Of The Year” by BioTech Breakthrough Awards

September 26, 2023

Strata Oncology Announces Appointment of Goz Alhir as Senior Vice President of Commercialization

September 11, 2023

Dr. Nair on the clinical utility of Immunotherapy Response Score 

September 10, 2023

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

September 7, 2023

Strata Oncology Announces New Data Supporting Utility of Immunotherapy Response Score to Guide First-Line Treatment Decisions in Non-small Cell Lung Cancer

July 10, 2023

Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

July 3, 2023

Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit

June 14, 2023

Dr Thomas on the Predictive Value of IRS For Pembrolizumab Benefit in Advanced Solid Tumors

June 1, 2023

Evaluation of Immunotherapy Response Score (IRS) for Predicting Pembrolizumab (pembro) Clinical Benefit in Patients (pts) with Advanced Solid Tumors